Anemia due to losartan in hypertensive renal transplant recipients without posttransplant erythrocytosis

Simple item page
dc.contributor.buuauthorErsoy, Alparslan
dc.contributor.buuauthorKahvecioğlu, Serdar
dc.contributor.buuauthorErsoy, Cihangir
dc.contributor.buuauthorÇift, Ali
dc.contributor.buuauthorDilek, Kamil
dc.contributor.departmentUludağ Üniversitesi/Tıp Fakültesi/Nefroloji Anabilim Dalı.tr_TR
dc.contributor.departmentUludağ Üniversitesi/Tıp Fakültesi/Endokrinoloji ve Metabolizma Anabilim Dalı.tr_TR
dc.contributor.departmentUludağ Üniversitesi/Tıp Fakültesi/Üroloji Anabilim Dalı.tr_TR
dc.contributor.orcid0000-0002-0710-0923tr_TR
dc.contributor.researcheridAAH-5054-2021tr_TR
dc.contributor.researcheridAAH-7103-2019tr_TR
dc.date.accessioned2021-09-10T12:38:15Z
dc.date.available2021-09-10T12:38:15Z
dc.date.issued2005-06
dc.description.abstractLosartan is a safe, effective long-term treatment for hypertension or posttransplant erythrocytosis (PTE) in renal transplant recipients. There were only a few studies in patients without PTE and their results were different. Starting from week 6 and continuing to the week 12 we observed a decrease in hemoglobin (Hb) and hematocrit (Hct) levels in patients without PTE. Anemia developed in 42.8% of the patients, and Hb levels increased after the withdrawal of losartan treatment. There was a significant decrease in Hct levels beginning from week 3 when compared with the control group. Our study suggests that losartan therapy can decrease Hb beyond its antihypertensive efficacy. Based on the capacity of losartan to decrease Hb and Hct, this drug should be carefully used in patients with preexistent anemia or low Hb levels.en_US
dc.identifier.citationErsoy, A. vd. (2005). "Anemia due to losartan in hypertensive renal transplant recipients without posttransplant erythrocytosis". Transplantation Proceedings, 37(5), 2148-2150.en_US
dc.identifier.endpage2150tr_TR
dc.identifier.issn0041-1345
dc.identifier.issue5tr_TR
dc.identifier.pubmed15964363tr_TR
dc.identifier.scopus2-s2.0-21844457129tr_TR
dc.identifier.startpage2148tr_TR
dc.identifier.urihttps://doi.org/10.1016/j.transproceed.2005.03.085
dc.identifier.urihttps://www.sciencedirect.com/science/article/pii/S0041134505003246
dc.identifier.urihttp://hdl.handle.net/11452/21866
dc.identifier.volume37tr_TR
dc.identifier.wos000230024800046tr_TR
dc.indexed.pubmedPubmeden_US
dc.indexed.scopusScopusen_US
dc.indexed.wosSCIEen_US
dc.language.isoenen_US
dc.publisherElsevier Scienceen_US
dc.relation.journalTransplantation Proceedingsen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergitr_TR
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectAngiotensin-IIen_US
dc.subjectImmunologyen_US
dc.subjectSurgeryen_US
dc.subjectTransplantationen_US
dc.subject.scopusKidney Transplantation; Anemias; Polycythemiaen_US
dc.subject.wosImmunologyen_US
dc.subject.wosSurgeryen_US
dc.subject.wosTransplantationen_US
dc.titleAnemia due to losartan in hypertensive renal transplant recipients without posttransplant erythrocytosisen_US
dc.typeArticle

Files

License bundle
Now showing 1 - 1 of 1
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description:
Download

Collections

Web of Science
Scopus